25 results about "Nicotine Addiction" patented technology

An subject of the present invention is (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine for use in in a method for the treatment of nicotine dependence in an amount of 0.1-5% by weight, a pharmaceutical composition comprising (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine for use in a method for the treatment of nicotine addiction in an amount of 0.1-5% by weight per composition of oral, inhalation and dermal products for humans. It is also an subject of the present invention to use a composition comprising (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine in an amount of 0.1-5% by weight as a substitute for a nicotine composition in food products, inhalation and dermal products for humans, the composition being in liquid or solid form and selected from such as e-cigarettes, e-cigarette liquids, chewing tobaccos, oral pouches, chewing gums, candies, lollipops, strips, dragees, jelly beans, lozenges, tablets, snuffs, shisha-type smoking mixtures, toothpastes, inhalation mixtures, inhalers or skin patches.

The invention discloses application of parthenolide in preparation of a medicine for preventing and / or treating nicotine addiction, and belongs to the technical field of medicines. Research finds that different doses of parthenolide can significantly prevent formation of nicotine-induced mouse CPP and formation of nicotine forced foraging; different doses of parthenolide can also significantly improve the withdrawal symptom of nicotine without affecting the spontaneous movement ability of mice, and meanwhile, parthenolide can also prevent nicotine from reburning. Therefore, parthenolide can be used for preparing the medicine for preventing and / or treating nicotine addiction.

This disclosure relates to an improved inhalable formulation comprising nicotine, or a pharmaceutically acceptable derivative or salt thereof, a propellant, a C1 to C6 alcohol and a glycol. The disclosure further relates to a metered dose inhaler containing the inhalable nicotine formulation and a method of treating a nicotine addiction with the formulation.

The invention discloses a composite probiotic preparation capable of improving sensitivity of low-dose nicotine and reducing usage amount of nicotine, and belongs to the crossing field of microbial technology and biological medicine. The compound probiotic preparation only improves the sensitivity of mice to low-concentration nicotine, does not improve the preference of the mice to the existing preference concentration, prevents aggravated smoking addiction, enables individuals to reach the satisfaction of smoking at ordinary times under the condition of low dosage of nicotine, and has the advantages of being simple in preparation process, low in cost and the like. The formulations may be used in combination with products in nicotine replacement therapy or alone. The compound probiotic preparation disclosed by the invention can be used for preparing functional foods, health-care products and medicines capable of improving the sensitivity of the low-concentration nicotine, and has a very wide application prospect.

The invention is applicable to the technical field of neuroscience, and provides a functional brain network determination method, device and equipment for nicotine addiction intervention, and the method comprises the following steps: respectively collecting resting-state electroencephalogram signals of two groups of subjects under the guidance of a smoking normal form, preprocessing the collected resting-state electroencephalogram signals, and determining the resting-state electroencephalogram signals of the two groups of subjects according to the preprocessed resting-state electroencephalogram signals; electroencephalogram micro-state analysis is carried out on all the obtained processed electroencephalogram signals, a group micro-state template and corresponding micro-state features are obtained, and micro-state conversion pairs with statistical significance are screened out through bidirectional interaction analysis of a linear mixing effect model constructed according to the micro-state features; and performing brain power analysis on the group micro-state template corresponding to the micro-state transition pair, and determining a functional brain network related to neural feedback training for nicotine addiction intervention, thereby realizing more precise capture of subtle changes of brain function states before and after neural feedback treatment, and improving the accuracy of the neural feedback treatment. And a more objective and quantitative nerve marker is provided for revealing an intervention mechanism and optimizing a treatment strategy.

The technical solution relates to smoking accessories, namely electronic cigarettes, and can be used as a device for vaping and helping to combat nicotine addiction. The technical solution described provides effective tools for reducing nicotine (aerosol, vapor) consumption and dependence by informing the user about the processes of nicotine (aerosol, vapor) consumption (encouraging mindful consumption), engaging awareness mechanisms during use of the device, and using restriction mechanisms that prevent unlimited consumption.

Vaporizers and vaporizer systems, which can include a device in communication with a vaporizer, can include one or more features related to control of functions and / or features of the vaporizer. A method for operating a vaporizer device is provided. The method includes determining a delivery program for providing a first puff containing an amount of a first vaporizable material and a second puff containing an amount of a second vaporizable material. The first vaporizable material includes a first substance and the second vaporizable material does not include the first substance. The method includes providing a plurality of puffs based on the delivery program and including the first puff and the second puff. The method further includes receiving user feedback associated with the delivery program in response to the providing. The method further includes modifying the delivery program based on the user feedback.

An intraoral formulation is provided that includes a solid, porous, chemically bonded ceramic system, nicotine or a salt thereof, and a pH modifier, where the chemically bonded ceramic system is formed in the absence of the pH modifier. The formulation includes nicotine and has particular utility in aiding smoking cessation, treating nicotine dependence, alleviating the symptoms of nicotine dependence, and in other medical uses for which nicotine is known.

This invention discloses a nicotine-capturing smoking cessation drug composition based on molecular configuration matching, belonging to the field of smoking cessation drug technology. The drug consists of three organic functional molecules screened by molecular structure (each molecule has a specific configuration, see Figure 2) that self-assemble in a specific molar ratio under human physiological conditions to form a three-dimensional molecular cage. This molecular cage, through precise adaptation of its internal cavity configuration to the chair conformation of nicotine molecules (the configuration after binding is shown in Figure 3), specifically recognizes and encapsulates nicotine molecules, preventing them from crossing the blood-brain barrier and entering the brain by increasing molecular weight and enhancing polarity. This blocks the nicotine addiction reward pathway at its source, thereby eliminating nicotine addiction and physiological dependence. The drug of this invention only acts in the peripheral circulation, does not enter the central nervous system, does not act on brain nerve receptors, has no psychotropic side effects, and is non-addictive. The molecular cage-nicotine complex can be normally metabolized and completely excreted from the body. This invention, with precise molecular configuration matching as its core innovation, has a novel mechanism, extremely high safety, and gentle withdrawal, effectively reducing relapse rates. It is suitable for various nicotine-dependent populations and has extremely high clinical translational and patent protection value.

The invention provides a nicotine degrading enzyme mutant as well as a preparation method and application thereof. The invention provides a recombinant nicotine degrading enzyme mutant. On the basis of NicA2 with an amino acid sequence as shown in SEQ ID NO: 1, mutation is carried out at any one of the following positions: the 48th position, the 379th position, the 189th position, the 208th position, the 234th position, the 274th position, the 317th position, the 369th position, the 370th position, the 362th position, the 396th position, the 462th position and the 479th position. Compared with a wild type nicotine degrading enzyme, the mutant has the advantages that the nicotine degrading activity is obviously improved, and the mutant has higher application potential in the aspects of further preparing a medicine for treating nicotine addiction or nicotine poisoning and improving the nicotine degrading activity and stability.

Salts of cytisine have been prepared and incorporated in stable pharmaceutical compositions, including compositions comprising lactose. The salts are prepared by adding acid stock solutions to solutions of cytisine with heating, followed by cooling to ambient temperature. The salts and compositions are indicated in the treatment of nicotine addiction.

The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH regulator selected from the group consisting of inorganic acids, inorganic buffers, and salts of inorganic acids, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention also relates to the liquid pharmaceutical composition for use in the treatment of tobacco addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco addiction and other forms of nicotine addiction.

This invention relates to the field of health management technology and discloses an intelligent smoking cessation management system, including an intelligent terminal and a cloud server that establish an information interaction connection. The intelligent terminal includes a user terminal and a consultant terminal. The consultant terminal and the user terminal interact with each other through the cloud server. The user terminal includes a nicotine addiction self-testing module, a daily micro-testing module, a health tool module, a consultation module, a nicotine addiction index module, and a recording module. The nicotine addiction self-testing module is used to measure the user's nicotine addiction level and generate quantitative nicotine addiction data. The daily micro-testing module is used to collect self-testing data. The health tool module is used to record factors affecting smoking cessation and generate smoking cessation behavior data. The consultation module is used for user-consultant interaction. The nicotine addiction index module is used to statistically analyze and visualize the user's current nicotine addiction index data. The recording module is used to record the user's adverse reactions during the smoking cessation process. This invention can achieve intelligent, personalized, and comprehensive smoking cessation management.

An subject of the present invention is (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine for use in in a method for the treatment of nicotine dependence in an amount of 0.1-5% by weight, a pharmaceutical composition comprising (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine for use in a method for the treatment of nicotine addiction in an amount of 0.1-5% by weight per composition of oral, inhalation and dermal products for humans.It is also an subject of the present invention to use a composition comprising (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine in an amount of 0.1-5% by weight as a substitute for a nicotine composition in food products, inhalation and dermal products for humans, the composition being in liquid or solid form and selected from such as e-cigarettes, e-cigarette liquids, chewing tobaccos, oral pouches, chewing gums, candies, lollipops, strips, dragees, jelly beans, lozenges, tablets, snuffs, shisha-type smoking mixtures, toothpastes, inhalation mixtures, inhalers or skin patches.Another subject of the present invention is a method of therapeutic treatment of nicotinic addiction in humans, characterised in that the treated patient is administered (S)-2-methyl-5-(1-methyl-2-pyrrolidinyl)pyridine in an amount of 0.1-5% by weight.

This disclosure relates to dosage forms comprising: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; and 2) about 25-35 mg, about 29-31 mg, about 30 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. In some embodiments, a dosage form as described herein is free of a Compound I and Compound II. In some embodiments, a dosage form may contain 0.5 ng to 750 ng of Compound I, 0.5 ng to 750 ng of Compound II, or a combination thereof. These dosage forms may be used to treat various neurological and psychiatric conditions, including major depressive disorder, agitation associated with Alzheimer's disease, and nicotine addiction.

This application relates to novel processes for treating persons who are cigarette smokers or are otherwise suffering from nicotine addiction. This application also relates to novel computer programs for artificial intelligence for the treatment of nicotine addition, as well as novel data structures and methods for the implementation of same. This application also relates to a novel formulation of liquid drops for application to filter cigarettes to block nicotine and / or tar from user inhalation.

The present application discloses an artificial enzyme, which is prepared based on sequence modification of a natural enzyme having the activity of catalyzing the reaction of converting compound I (nicotine) into compound II (N-methyl-4-hydroxy-3-methylnicotinamide) shown as follows, and compound II (N-methyl-4-hydroxy-3-methylnicotinamide) can spontaneously hydrate to generate compound III (pseudo-oxidized nicotine), or the natural enzyme is nicotine dehydrogenase; the modification includes replacing at least one of the amino acids that hinder the release of the product with an amino acid with a smaller side chain. The artificial enzyme has a higher catalytic rate on the substrate than the natural enzyme, and is very promising in the preparation of drugs for treating nicotine addiction.

The subject of the application is a dietary food in the form of a functional powder for reducing nicotine craving, which is characterized in that it contains L-theanine in an amount of 2% to 6% of the total weight of the powder, as an ingredient supporting stress reduction and alleviating nicotine withdrawal symptoms, L-tyrosine in an amount of 5% to 10% of the total weight of the powder, supporting mood stabilization by increasing dopamine levels, kudzu extract in an amount of 1% to 4% of the total weight of the powder, which acts on reducing compulsive behaviors associated with nicotine addiction, Glucomannan in an amount of 10% to 20% of the total weight of the powder, promoting the feeling of satiety and regulating eating habits during the withdrawal period, carriers and excipients, such as maltodextrin and microcrystalline cellulose, in an amount of 60% to 80% of the total weight of the powder, ensuring form stability and ease of use.The preparation is intended to reduce nicotine cravings and support emotional balance in people addicted to tobacco products, especially during nicotine withdrawal.

According to the invention, the original traditional Chinese medicine preparation compound 511 for resisting morphine addiction is subjected to medicine taste addition and subtraction to form a new compound 511, and the medicine effect of resisting nicotine addiction is explored. A new compound 511 is formed on the basis of mechanism overlapping between opioid drugs and nicotine in a midbrain marginal dopaminergic system and in combination with experimental results of an earlier-stage research group, and the new compound 511 is guessed to be possibly capable of intervening in nicotine addiction. The novel compound 511 is safe in medication, can effectively intervene in formation of nicotine addiction, and also can remarkably inhibit decline of spontaneous movement of mice caused by stopping administration after nicotine addiction. Meanwhile, pathological injuries of liver, heart, spleen, lung, kidney and ileum organs caused by nicotine addiction dosage can be improved. In addition, the composition medicines of the compound are simpler, the curative effect is definite, the price is moderate, the economic burden of smoking cessation patients can be reduced, and the compound has a very good commercial prospect.

This invention provides smoking cessation support methods and systems to help smokers quit. [Solution] A method for supporting smoking cessation that clarifies the structure of nicotine addiction that hinders the achievement of smoking cessation into three elements: physical dependence, psychological dependence, and conditioned reflexes, and implements smoking cessation support in this order, comprising: a first step of presenting first information; a first determination step of determining whether the physical dependence has been overcome after a first predetermined period has elapsed since the presentation of the first information, and if the physical dependence has been overcome, proceeding to a second smoking cessation support for the psychological dependence; a second step of presenting second information; a second determination step of determining whether the psychological dependence has been overcome after a second predetermined period has elapsed since the presentation of the second information, and if the psychological dependence has been overcome, proceeding to a third smoking cessation support for the conditioned reflexes; and a third step of presenting third information.

The present invention is applicable to the field of neuroscience technology and provides a method, device and equipment for determining functional brain networks for nicotine addiction intervention. The method includes: respectively collecting resting-state EEG signals from subjects in two groups under the guidance of a smoking paradigm, preprocessing each collected resting-state EEG signal, performing EEG microstate analysis on all processed EEG signals to obtain a group microstate template and corresponding microstate characteristics, screening out statistically significant microstate transition pairs through two-way interaction analysis of a linear mixed-effects model constructed based on the microstate characteristics, performing EEG source analysis on the group microstate templates corresponding to the microstate transition pairs, and determining functional brain networks related to neurofeedback training for nicotine addiction intervention, thereby more accurately capturing the subtle changes in brain functional state before and after neurofeedback treatment, and providing more objective and quantitative neural markers for revealing its intervention mechanism and optimizing treatment strategies.

The present disclosure relates to a chemical compound having the general formula (I):wherein R1 is a phenyl group and R2 is a meta-substituted phenyl group; and RTA is a substituted or unsubstituted thiazole ring. The disclosure also relates to said compound according to formula (I), in particular in its diastereomerically pure or enriched form, for use in therapy, in particular for treating and / or preventing age-related cognitive decline. Further, the disclosure relates to said compound according to formula (I) for use in improving cognitive functions, in particular for use in improving the spatial learning capabilities in human individuals. And, disclosure also relates to said compound according to formula (I) for use in the treatment and / or prevention of alcohol addiction, nicotine addiction and / or drug addiction, in particular cocaine and / or metamphetamine addiction.

To provide a smoking cessation support method for supporting smoking cessation of smokers, and a smoking cessation support system.SOLUTION: A smoking cessation support method for clarifying a structure of nicotine dependence for inhibiting achievement of smoking cessation, into three elements of physical dependence, psychological dependence and conditioned reflex, and executing smoking cessation support in this order, includes: a first step of presenting first information; a first determination step of determining whether or not the physical dependence has been overcome after the lapse of a first prescribed period from the presentation of the first information, and when the physical dependence has been overcome, proceeding to a second smoking cessation support for the psychological dependence; a second step of presenting second information; a second determination step of determining whether or not the psychological dependence has been overcome after the lapse of a second prescribed period from the presentation of the second information and when the psychological dependence has been overcome, proceeding to a third smoking cessation support for the conditioned reflex; and a third step of presenting third information.SELECTED DRAWING: Figure 5

To provide a novel salt of cytisine, and to provide pharmaceutical compositions comprising the salt, in particular, to provide a salt of cytisine which displays improved excipient compatibility, permitting the preparation of stable pharmaceutical compositions.SOLUTION: Provided is a succinate salt of cytisine, the salt being in the form of a solvate or hydrate. Further provided is a pharmaceutical composition comprising the salt and a pharmaceutically acceptable excipient, the pharmaceutical composition being in the form of a tablet or a capsule, the pharmaceutical composition being provided as a unit dosage form, the unit dosage form comprising 1 mg to 3 mg of cytisine hydrogen succinate, and the pharmaceutical composition being for use in the treatment of nicotine addiction.SELECTED DRAWING: None